News

ROX Medical adds 15th Clinical site, in Netherlands, to CONTROL-HTN randomized study

ROX Medical this week received confirmation of Ethics Committee approval at St. Antonius Hospital, Netherlands making it the 15th clinical center in the ROX CONTROL-HTN randomized study. St. Antonius will join centers across the UK, Belgium, Ireland, Germany, Poland and Greece. The CONTROL-HTN randomized study is a 100-patient trial to evaluate the ROX arterio-venous Coupler used along with standard drug therapy to treat resistant hypertension. The study is over 25% enrolled and is projected to complete enrollment before year-end.

roxmedicalusROX Medical adds 15th Clinical site, in Netherlands, to CONTROL-HTN randomized study
read more

ROX Medical Enrolls First Patient in Randomized Controlled Hypertension Trial of AV-Coupler

ROX Medical announced the first patient enrollment in the CONTROL-HTN international randomized controlled trial of the ROX FLOW procedure for the treatment of resistant hypertension (high blood pressure). The first patient was enrolled at the Universitair Ziekenhuis Brussel (University Hospital of Brussels) Brussels, Belgium by Professor Danny Schoors and Dr Sofie Brouwers.

Read Study Here

roxmedicalusROX Medical Enrolls First Patient in Randomized Controlled Hypertension Trial of AV-Coupler
read more

Dr. Sofie Brouwers presents the ROX COPD/HTN data at Austin Doyle Award Session at ISH 2012, Sydney, Australia

Dr. Sofie Brouwers from UZ Brussel, Belgium was selected to present at the prestigious Austin Doyle Award Session during the 2012 International Symposium of Hypertension (ISH) in Sydney, Australia. Dr. Brouwers presented the 12-month data from the ROX Medical US IDE and German Multicenter study on patients with concomitant COPD and Hypertension. The resulting data explored the associated blood pressure reduction after the creation of an iliofemoral fistula. The data showed that the creation of a calibrated iliofemoral AVF significantly reduced blood pressure after 3 and 6 months and that the reduction was maintained at 12 months.

Read the abstract here:  2012 ISH Austin Doyle Award Session

roxmedicalusDr. Sofie Brouwers presents the ROX COPD/HTN data at Austin Doyle Award Session at ISH 2012, Sydney, Australia
read more

ROX Medical Announces First Clinical Use of the ROX FLOW Procedure for the Treatment of High Blood Pressure in Resistant Hypertension Patients

ROX Medical, Inc. today announced the first clinical use of the ROX COUPLER TM at the Universitair Ziekenhuis Brussel (University Hospital of Brussels) to treat resistant hypertension. “We are pleased to have performed the first ever ROX FLOW Procedure for this new approach to hypertension, the acute impact on the patients’ blood pressure was greater than we expected and we look forward to understanding how much these patients benefit from the treatment over time.”

roxmedicalusROX Medical Announces First Clinical Use of the ROX FLOW Procedure for the Treatment of High Blood Pressure in Resistant Hypertension Patients
read more